{
    "nct_id": "NCT04982926",
    "official_title": "A Phase 1 Study of TAS2940 in Patients With Locally Advanced or Metastatic Solid Tumors With EGFR and / or HER2 Aberrations",
    "inclusion_criteria": "* Have histologically confirmed solid cancer that is locally advanced and metastatic and available standard treatment options have been exhausted\n* Have adequate organ function\n* ECOG PS 0-1\n\nDose Escalation:\n\n* Have measurable or non- measurable disease per RECIST criteria v1.1 or RANO\n* Any solid tumor with EGFR and / or HER2 aberration\n\nDose Expansion:\n\n* Have measurable disease per RECIST criteria v1.1 for solid tumor (excluding primary brain tumor) or RANO (for glioblastoma)\n* Cohort A: Non-small cell lung cancer (NSCLC)\n* Cohort B: HER2 positive breast cancer\n* Cohort C: Recurrent or refractory glioblastoma\n* Cohort D: Other solid tumors with EGFR or HER2 aberrations\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Non-stable brain metastases\n* Have significant cardiovascular disorder\n* Have not recovered from prior cancer treatment\n* A serious illness or medical condition",
    "miscellaneous_criteria": ""
}